What Is AN2 Therapeutics, Inc. (ANTX) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on AN2 Therapeutics, Inc. at its current price of $4.55. The composite intrinsic value is estimated at $4.83 (+6.2% average return), with 4 models flagging overvaluation risk. The most optimistic model, First Chicago, places fair value at $12.02 (+164.3%), while ML-RIV — the most conservative — estimates $1.00 (-77.9%). This +242.2% gap reflects genuine analytical uncertainty about AN2 Therapeutics, Inc.'s intrinsic worth.
What Do the Models Say About ANTX?
7 of 13 models are currently active for ANTX. Of these, 2 models suggest upside while 5 models suggest overvaluation. The Bayesian DCF estimates ANTX's intrinsic value at $2.75, implying -39.6% downside from the current price. See which stocks rank higher →
How Does ANTX Rank in Biotechnology?
Among 62 Biotechnology stocks, ANTX ranks #42 by Quality of Company score. CirclFi's QOC score of 4.4/10 evaluates 32 fundamental signals. A score of 4.4 reflects mixed fundamentals.
See all Most Undervalued Biotechnology Stocks →
Within the Biotechnology space, AN2 Therapeutics, Inc. competes in an environment where partnership revenue often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is ANTX a Value Trap?
CirclFi's Value Trap algorithm assigns ANTX a score of 18/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
7 of 13 models are active for AN2 Therapeutics, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, AN2 Therapeutics, Inc. is rated at 4.4/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.
The gap between the most bullish and bearish model spans +242.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every ANTX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across ANTX's 7 active models, average confidence is 25%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad